Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNSTNASDAQ:ICPTNASDAQ:RTRXNASDAQ:ZGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/ARTRXTravere Therapeutics$5.45-5.1%$26.56$8.98▼$24.96$278.23M0.67412,277 shs2.78 million shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%+3.37%RTRXTravere Therapeutics-5.05%-9.02%-30.84%-39.85%-74.17%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AICPTIntercept Pharmaceuticals0.3421 of 5 stars1.00.00.03.90.01.70.6RTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation PharmaceuticalsN/AN/AN/AN/AICPTIntercept Pharmaceuticals2.00Hold$19.864.51% UpsideRTRXTravere TherapeuticsN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/AICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05RTRXTravere Therapeutics$175.34M1.59N/AN/A$5.15 per share1.06ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/AICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/ARTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/AZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39ICPTIntercept Pharmaceuticals3.124.222.52RTRXTravere Therapeutics0.667.237.14ZGNXZogenix0.883.634.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/AICPTIntercept Pharmaceuticals83.81%RTRXTravere TherapeuticsN/AZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%ICPTIntercept Pharmaceuticals6.20%RTRXTravere Therapeutics4.63%ZGNXZogenix4.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableZGNXZogenix21856.23 million53.92 millionOptionableICPT, CNST, ZGNX, and RTRX HeadlinesSourceHeadlineHwasung Industrial Co Ltd 002460morningstar.com - March 23 at 1:30 AMOrally Inhaled Dihydroergotaminemedscape.com - February 13 at 4:11 PMMRI in Headachemedscape.com - August 25 at 10:47 PMKratom: What We Knowmedscape.com - August 13 at 5:03 PMAlcon (NYSE: ALC)fool.com - July 6 at 8:34 PMLongeveron Inc Ordinary Shares - Class Amorningstar.com - May 21 at 12:24 AMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journalnews.google.com - May 10 at 11:58 PMGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRnews.google.com - May 4 at 4:03 PMNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan Newsnews.google.com - April 28 at 12:42 PMThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headachemedscape.com - April 25 at 2:50 PMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan Newsnews.google.com - April 24 at 9:21 AMAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journalnews.google.com - April 24 at 9:21 AMDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journalnews.google.com - April 20 at 12:29 AMForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comnews.google.com - April 19 at 7:28 PMDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome Newsnews.google.com - April 18 at 3:52 PMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journalnews.google.com - April 17 at 7:30 PMSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journalnews.google.com - April 17 at 7:30 PMEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journalnews.google.com - April 17 at 9:27 AMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswirenews.google.com - April 17 at 9:27 AMLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRnews.google.com - April 14 at 8:40 AMNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journalnews.google.com - April 13 at 5:40 PMNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRnews.google.com - April 12 at 1:29 PMCompany DescriptionsConstellation PharmaceuticalsNASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Intercept PharmaceuticalsNASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.ZogenixNASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.